Education
About Us
Working with TipRanks
Follow Us
OncoTherapy Science, Inc. (DE:30O)
FRANKFURT:30O
Total Valuation
OncoTherapy Science has a market cap or net worth of €34.58M. The enterprise value is €7.94B.
Market Cap€34.58M
Enterprise Value€7.94B
Share Statistics
OncoTherapy Science has 275,643,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding275,643,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
OncoTherapy Science’s return on equity (ROE) is -1.12 and return on invested capital (ROIC) is -96.69%.
Return on Equity (ROE)-1.12
Return on Assets (ROA)-0.71
Return on Invested Capital (ROIC)-96.69%
Return on Capital Employed (ROCE)-0.96
Revenue Per Employee13.89M
Profits Per Employee-15.10M
Employee Count54
Asset Turnover0.65
Inventory Turnover9.67
Valuation Ratios
The current PE Ratio of OncoTherapy Science is -8.97. OncoTherapy Science’s PEG ratio is 0.14.
PE Ratio-8.97
PS Ratio0.00
PB Ratio10.59
Price to Fair Value10.03
Price to FCF-11.31
Price to Operating Cash Flow-11.39
PEG Ratio0.14
Income Statement
In the last 12 months, OncoTherapy Science had revenue of 750.05M and earned -815.28M in profits. Earnings per share was -3.12.
Revenue750.05M
Gross Profit-12.76M
Operating Income-797.94M
Pretax Income-813.13M
Net Income-815.28M
EBITDA-811.92M
Earnings Per Share (EPS)-3.12
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
OncoTherapy Science pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.69
52-Week Price Change-47.37%
50-Day Moving Average0.12
200-Day Moving Average0.14
Relative Strength Index (RSI)43.41
Average Volume (3m)10.00
Important Dates
OncoTherapy Science upcoming earnings date is Aug 1, 2025, TBA Not Confirmed.
Last Earnings DateFeb 7, 2025
Next Earnings DateAug 1, 2025
Ex-Dividend Date―
Financial Position
OncoTherapy Science as a current ratio of 3.37, with Debt / Equity ratio of 0.00%
Current Ratio3.37
Quick Ratio3.13
Debt to Market Cap<0.01
Net Debt to EBITDA0.96
Interest Coverage Ratio-664.39
Taxes
In the past 12 months, OncoTherapy Science has paid 2.16M in taxes.
Income Tax2.16M
Effective Tax Rate>-0.01
Enterprise Valuation
OncoTherapy Science EV to EBITDA ratio is -8.04, with an EV/FCF ratio of -8.01.
EV to Sales8.71
EV to EBITDA-8.04
EV to Free Cash Flow-8.01
EV to Operating Cash Flow-8.01
Balance Sheet
OncoTherapy Science has €945.00M in cash and marketable securities with ¥0.00 in debt, giving a net cash position of -€945.00M billion.
Cash & Marketable Securities€945.00M
Total Debt¥0.00
Net Cash-€945.00M
Net Cash Per Share-€3.43
Tangible Book Value Per Share€2.79
Margins
Gross margin is 3.67%, with operating margin of -106.38%, and net profit margin of -108.70%.
Gross Margin3.67%
Operating Margin-106.38%
Pretax Margin-108.41%
Net Profit Margin-108.70%
EBITDA Margin-108.25%
EBIT Margin-108.25%
Analyst Forecast
The average price target for OncoTherapy Science is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―